Protium heptaphyllum Aubl. belongs to the Burseraceae family. It is commonly called 'almecegueira' and is known to produce an amorphous resin which has constituents such as α- and β-amyrin, taraxastan-3-oxo-20-ol and sitostenonein. The α- and β-amyrin from P. heptaphyllum have pharmacological activities in several systems, such as central and peripheral nervous system, gastrointestinal tract and immunological system. In this study, our objective was to review pharmacological activities and to gather more information on the mixture of α- and β-amyrin obtained from P. heptaphyllum to guide future preclinical and clinical studies using this compound. This review consisted of searches performed using scientific databases such as PubMed, SciELO, LILACS, SciFinder and Science Direct. Some uses of α- and β-amyrin have been partially confirmed by previous studies demonstrating analgesic, anti-inflammatory, anticonvulsant, antidepressive, gastroprotective, hepatoprotective, antipancreatitic, anticholytic, antihyperglycemic and hypolipidemic effects. It is noteworthy that there are no α- and β-amirin toxicity tests described in the literature as recommended in the international guidelines, and such tests are one of the research stages to proceed in clinical and preclinical trials if this compound was to be used.

No abstract

No abstract

Objective: to identify drug associations related to the scheduling of antibiotics in the neonatal unit which may cause drug interactions. Methods: a retrospective documentary study using medical records of newborns admitted into the neonatal unit. The sample was composed of 92 newborn medical records. Data were collected through forms and presented in tables and figures. Results: associations in drug scheduling leading to pharmacokinetic interactions were found in 24 medical records, highlighting associations between amikacin and ampicillin, cefepime and furosemide, and vancomycin and furosemide. Conclusion: the scheduling of drugs at the same time represents a risk to newborn's health due to the possibility of drug interactions.